SEC Form 3 · accession 0001437749-26-027363

Eton Pharmaceuticals, Inc. · ETON

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Danka Radosavljevic

Officer — Chief Operating Officer

Period of report

Jul 31, 2026

Accepted (ET)

Aug 12, 2026 · 5:00 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001710340

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	holding	—	—		—	22,473	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Buy)^F1	$15.47	holding	—	—	—	—	Jan 11, 2036	Common Stock	31,508	—	D
Restricted Stock Units^F3,F2	$0.00	holding	—	—	—	—	—	Common Stock	20,039	—	D
Restricted Stock Units^F3,F4	$0.00	holding	—	—	—	—	—	Common Stock	7,194	—	D
Employee Stock Option (Right to Buy)^F5	$13.00	holding	—	—	—	—	Jan 2, 2035	Common Stock	14,317	—	D
Employee Stock Option (Right to Buy)^F6	$14.68	holding	—	—	—	—	Mar 17, 2035	Common Stock	10,000	—	D
Employee Stock Option (Right to Buy)^F7	$4.42	holding	—	—	—	—	Feb 12, 2034	Common Stock	92,993	—	D
Employee Stock Option (Right to Buy)^F8	$4.74	holding	—	—	—	—	Aug 14, 2033	Common Stock	10,000	—	D
Employee Stock Option (Right to Buy)^F9	$3.47	holding	—	—	—	—	Feb 19, 2033	Common Stock	42,224	—	D
Employee Stock Option (Right to Buy)^F10	$8.61	holding	—	—	—	—	May 2, 2031	Common Stock	35,000	—	D
Employee Stock Option (Right to Buy)^F11	$3.58	holding	—	—	—	—	Mar 11, 2030	Common Stock	60,000	—	D
Employee Stock Option (Right to Buy)^F12	$1.38	holding	—	—	—	—	Jul 23, 2027	Common Stock	18,742	—	D
Common Stock^F13	$0.00	holding	—	—	—	—	—	Common Stock	128,985	—	D

Explanation of responses

F1The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 12, 2030.
F10The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on May 3, 2025.
F11The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on March 12, 2024.
F12The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on July 24, 2021.
F13On July 31, 2026, the reporting person was granted 128,985 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029. The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.
F2The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting.
F3Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock.
F4The restricted stock units vest in four equal annual installments beginning January 3, 2026, contingent upon the reporting person being employed by the issuer on the date(s) of vesting.
F5The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 3, 2029.
F6The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on March 18, 2029.
F7The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on February 13, 2028.
F8The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on August 15, 2027.
F9The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on February 20, 2027.

Remarks

The reporting person has authorized and designated the named person to file this Form 3 on the reporting person's behalf for indefinite duration.